These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 24512128)

  • 1. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.
    Cao L; Li LS; Spruell C; Xiao L; Chakrabarti G; Bey EA; Reinicke KE; Srougi MC; Moore Z; Dong Y; Vo P; Kabbani W; Yang CR; Wang X; Fattah F; Morales JC; Motea EA; Bornmann WG; Yordy JS; Boothman DA
    Antioxid Redox Signal; 2014 Jul; 21(2):237-50. PubMed ID: 24512128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
    Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
    Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer.
    Li LS; Reddy S; Lin ZH; Liu S; Park H; Chun SG; Bornmann WG; Thibodeaux J; Yan J; Chakrabarti G; Xie XJ; Sumer BD; Boothman DA; Yordy JS
    Mol Cancer Ther; 2016 Jul; 15(7):1757-67. PubMed ID: 27196777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
    Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
    Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.
    Chakrabarti G; Silvers MA; Ilcheva M; Liu Y; Moore ZR; Luo X; Gao J; Anderson G; Liu L; Sarode V; Gerber DE; Burma S; DeBerardinis RJ; Gerson SL; Boothman DA
    Sci Rep; 2015 Nov; 5():17066. PubMed ID: 26602448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isopentyl-Deoxynboquinone Induces Mitochondrial Dysfunction and G2/M Phase Cell Cycle Arrest to Selectively Kill
    Jiang L; Liu Y; Tumbath S; Boudreau MW; Chatkewitz LE; Wang J; Su X; Zahid KR; Li K; Chen Y; Yang K; Hergenrother PJ; Huang X
    Antioxid Redox Signal; 2024 Jul; 41(1-3):74-92. PubMed ID: 37950707
    [No Abstract]   [Full Text] [Related]  

  • 7. NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers.
    Motea EA; Huang X; Singh N; Kilgore JA; Williams NS; Xie XJ; Gerber DE; Beg MS; Bey EA; Boothman DA
    Clin Cancer Res; 2019 Apr; 25(8):2601-2609. PubMed ID: 30617135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct responses of compartmentalized glutathione redox potentials to pharmacologic quinones targeting NQO1.
    Kolossov VL; Ponnuraj N; Beaudoin JN; Leslie MT; Kenis PJ; Gaskins HR
    Biochem Biophys Res Commun; 2017 Jan; 483(1):680-686. PubMed ID: 27986568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NAD(P)H:quinone oxidoreductase 1 determines radiosensitivity of triple negative breast cancer cells and is controlled by long non-coding RNA NEAT1.
    Lin LC; Lee HT; Chien PJ; Huang YH; Chang MY; Lee YC; Chang WW
    Int J Med Sci; 2020; 17(14):2214-2224. PubMed ID: 32922184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-Lapachone promotes the recruitment and polarization of tumor-associated neutrophils (TANs) toward an antitumor (N1) phenotype in NQO1-positive cancers.
    Tumbath S; Jiang L; Li X; Zhang T; Zahid KR; Zhao Y; Zhou H; Yin Z; Lu T; Jiang S; Chen Y; Chen X; Fu YX; Huang X
    Oncoimmunology; 2024; 13(1):2363000. PubMed ID: 38846085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
    Silvers MA; Deja S; Singh N; Egnatchik RA; Sudderth J; Luo X; Beg MS; Burgess SC; DeBerardinis RJ; Boothman DA; Merritt ME
    J Biol Chem; 2017 Nov; 292(44):18203-18216. PubMed ID: 28916726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells.
    Choi EK; Terai K; Ji IM; Kook YH; Park KH; Oh ET; Griffin RJ; Lim BU; Kim JS; Lee DS; Boothman DA; Loren M; Song CW; Park HJ
    Neoplasia; 2007 Aug; 9(8):634-42. PubMed ID: 17786182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Albumin binding revitalizes NQO1 bioactivatable drugs as novel therapeutics for pancreatic cancer.
    Dou L; Liu H; Wang K; Liu J; Liu L; Ye J; Wang R; Deng H; Qian F
    J Control Release; 2022 Sep; 349():876-889. PubMed ID: 35907592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. beta-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3.
    Planchon SM; Pink JJ; Tagliarino C; Bornmann WG; Varnes ME; Boothman DA
    Exp Cell Res; 2001 Jul; 267(1):95-106. PubMed ID: 11412042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.
    Li LS; Bey EA; Dong Y; Meng J; Patra B; Yan J; Xie XJ; Brekken RA; Barnett CC; Bornmann WG; Gao J; Boothman DA
    Clin Cancer Res; 2011 Jan; 17(2):275-85. PubMed ID: 21224367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy.
    Miyamoto S; Huang TT; Wuerzberger-Davis S; Bornmann WG; Pink JJ; Tagliarino C; Kinsella TJ; Boothman DA
    Ann N Y Acad Sci; 2000; 922():274-92. PubMed ID: 11193903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation.
    Park HJ; Ahn KJ; Ahn SD; Choi E; Lee SW; Williams B; Kim EJ; Griffin R; Bey EA; Bornmann WG; Gao J; Park HJ; Boothman DA; Song CW
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):212-9. PubMed ID: 15629614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmented Concentration of Isopentyl-Deoxynyboquinone in Tumors Selectively Kills NAD(P)H Quinone Oxidoreductase 1-Positive Cancer Cells through Programmed Necrotic and Apoptotic Mechanisms.
    Wang J; Su X; Jiang L; Boudreau MW; Chatkewitz LE; Kilgore JA; Zahid KR; Williams NS; Chen Y; Liu S; Hergenrother PJ; Huang X
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Following anticancer drug activity in cell lysates with DNA devices.
    Kahanda D; Singh N; Boothman DA; Slinker JD
    Biosens Bioelectron; 2018 Nov; 119():1-9. PubMed ID: 30098460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unlocking the effective alliance of β-lapachone and hydroxytyrosol against triple-negative breast cancer cells.
    Calahorra J; Blaya-Cánovas JL; Castellini-Pérez O; Aparicio-Puerta E; Cives-Losada C; Marin JJG; Rementeria M; Cara FE; López-Tejada A; Griñán-Lisón C; Aulicino F; Berger I; Marchal JA; Delgado-Almenta V; Granados-Principal S
    Biomed Pharmacother; 2024 May; 174():116439. PubMed ID: 38518601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.